Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse.
We set out to develop a PSA peptide-loaded tetramer for enumeration of PSA-specific CD8(+) T cells in the Balb/c mouse model. A candidate major histocompatibility complex (MHC) class I PSA peptide (HPQKVTKFML(188-197)) was selected on the basis of its ability to restimulate PSA-specific CD8(+) T cells to secrete interferon-γ in our assays. Next, H-2L(d)-restricted peptide-loaded and fluorescently labeled tetramers were produced in conjunction with the NIH Tetramer Core Facility, Atlanta, GA, USA. This tetramer was then tested for staining specificity and optimized for detection of PSA-specific CD8(+) T cells induced by our PSA-encoding adenovirus tumor vaccine. The MHC class I PSA peptide demonstrated successful restimulation of CD8(+) T cells isolated from mice previously vaccinated with a PSA-encoding adenovirus tumor vaccine, with no restimulation observed in control-vaccinated mice. The peptide-loaded H-2L(d) tetramer exhibited the desired binding specificity and allowed for detection and frequency determination of PSA-specific CD8(+) T cells by flow cytometry. We have successfully designed and validated a PSA peptide tetramer for use in the Balb/c mouse model that can be used to test PSA-based prostate cancer vaccines. Until now, PSA-specific CD8(+) T cells in the mouse have only been detectable via cytotoxic T-lymphocyte assays or intracellular cytokine staining, which primarily assess antigen-specific functional activity and not their absolute number. This research tool provides laboratories the ability to directly quantitate CD8(+) T cells elicited by PSA-specific immunotherapies and cancer vaccines that are tested in mouse models.
College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
C D
CD
Lemke
J B
JB
Graham
D M
DM
Lubaroff
A K
AK
Salem
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000737:chemistry / Q000276:immunology; D007167:Immunotherapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018448:Models, Immunological; D010446:Peptide Fragments / Q000276:immunology*; D017430:Prostate-Specific Antigen / Q000276:immunology*; D020836:Protein Structure, Quaternary; D013194:Staining and Labeling
D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D010446:Peptide Fragments; D017430:Prostate-Specific Antigen
J Clin Invest. 2004 Mar;113(5):774-83
14991076
Nat Rev Cancer. 2008 Apr;8(4):299-308
18354418
J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900
9862627
Eur J Immunol. 2006 Feb;36(2):468-77
16385625
J Exp Med. 2007 Feb 19;204(2):345-56
17261634
Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents
20152525
Cancer Res. 2002 Sep 15;62(18):5260-6
12234994
Immunol Rev. 1981;60:5-22
6171504
Curr Opin Immunol. 1995 Feb;7(1):85-96
7772286
Sci STKE. 2004 Jul 06;2004(241):pe28
15252217
Clin Cancer Res. 2001 Mar;7(3 Suppl):882s-889s
11300487
Science. 1996 Oct 4;274(5284):94-6
8810254
Adv Cancer Res. 1992;58:143-75
1532109
J Immunol Methods. 2001 Oct 1;256(1-2):107-19
11516759
Eur J Immunol. 2009 Oct;39(10):2725-36
19637230
J Immunol. 2000 Jul 1;165(1):539-47
10861094
J Immunol. 2001 Jan 15;166(2):731-5
11145643
Curr Protoc Immunol. 2003 May;Chapter 17:Unit 17.3
18432902
Int J Cancer. 2001 Dec 15;94(6):842-9
11745487
Vaccine. 2006 Aug 28;24(35-36):6155-62
16876291
Cancer Immunol Immunother. 2005 Nov;54(11):1082-94
16047142
Int J Cancer. 2007 Oct 1;121(7):1520-8
17565748
Blood Rev. 2006 Mar;20(2):61-9
15978709
Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74
19166887
Int J Cancer. 2009 Feb 15;124(4):877-88
19035460